ClinicalTrials.gg
CompletedNCT02477826CheckMate 227Updated Oct 30, 2025Results posted

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

A Phase 3 interventional study of Nivolumab and Ipilimumab in Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 290 sites in 33 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-30.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,747
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 44 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
2nd of 120
2,747 · median 66
Started
2015
with 8 others
Phase 3
24 of 120
3 open now
Registered
21st of 120
by date
Lead sponsor
28 of 120
Bristol-Myers Squibb

Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by enrollment, is one of 9 that started in 2015, is one of 24 in phase 3, and was the 21st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer.

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with confirmed Stage IV or recurrent NSCLC squamous or non-squamous histology, with no prior systemic anticancer therapy
  • Subjects must have programmed death-ligand 1 (PD -L1) immunohistochemical (IHC) testing, with results, performed by the central lab during the Screening period
  • (ECOG) Performance Status of ≤ 1
  • by CT or MRI per version 1.1 (RECIST 1.1) criteria

Exclusion criteria

Exclusion Criteria:

  • Subjects with untreated Central nervous system (CNS) are excluded
  • Subjects with an active, known or suspected disease are excluded
  • Any positive test for virus or virus or (HIV) indicating acute or chronic infection

Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,747 participants (actual)

Study arms

  • Experimental
    Arm A: Nivolumab

    Nivolumab intravenously (IV) as specified

    Drug: Nivolumab

  • Experimental
    Arm B: Nivolumab + Ipilimumab

    Nivolumab + Ipilimumab IV as specified

    Drug: Nivolumab · Drug: Ipilimumab

  • Experimental
    Arm C: Nivolumab + Platinum doublet chemotherapy

    Nivolumab + Platinum doublet chemotherapy (IV) dose as specified

    Drug: Nivolumab · Drug: Carboplatin · Drug: Cisplatin · Drug: Gemcitabine · Drug: Pemetrexed · Drug: Paclitaxel

  • Experimental
    Arm D: Platinum doublet chemotherapy

    Chemotherapy administered on specified days of IV chemotherapy

    Drug: Carboplatin · Drug: Cisplatin · Drug: Gemcitabine · Drug: Pemetrexed · Drug: Paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival Per BICR

    Progression-Free Survival then (PFS) is defined as the time between the date of randomization and the date of first documented disease progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first based on Kaplan-Meier estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 481 weeks)

  2. Overall Survival

    OS for all randomized participants is the time between randomization date and the date of death from any cause.

    Time frame: From randomization untill death or last follow up whichever occurs first (up to approximately 481 weeks)

Secondary outcomes

  1. Objective Response Rate (ORR) Per BICR

    Objective response rate (ORR) is defined as the number of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 481 weeks)

  2. Percentage of Participants With Symptom Deterioration at Week 12 Assessed Via Lung Cancer Symptom Scale

    The Lung Cancer Symptom Scale (LCSS) is a disease measure of quality of life which evaluates six major lung cancer symptoms and their effect on overall distress and symptom severity, impact on day-to-day activities, and overall quality of life. This patient reported outcome (PRO) questionnaire assesses the following 6 symptoms items (appetite loss, fatigue, cough, dyspnea, hemoptysis, pain) and 3 summary global items (symptom distress, activity level, overall quality of life) for patients using visual analogue scales (VAS) (100 mm horizontal line) ranging from 0 (best rating) to 100 (worst rating). The LCSS average total score is sum of items 1 to 9 divided by the total number of items ((sum of items 1 to 9)/9) ranging from 0 to 100 where high score represent worst outcome. Disease-Related Symptom Deterioration by Week 12 defined as a 10 points or more increase from baseline in LCSS average score at any time (on or off-treatment) up to 95 days from randomization date.

    Time frame: Week 12

07

Results

Posted Oct 30, 2025

Participant flow

Pre-Treatment
Participant flow — Pre-Treatment
MilestonePart 1-Arm B: Nivo + IpiPart 1-Arm A: NivolumabPart 1-Arm C: ChemotherapyPart 1-Arm D: Nivo + IpiPart 1-Arm G: Nivo + ChemoPart 1-Arm F: ChemotherapyPart 2 - Arm H: Nivolumab + ChemotherapyPart 2 - Arm I: ChemotherapyPart 3 -Arm J: Nivolumab + IpilimumabPart 3 - Arm K: Chemotherapy
Started396396397187177186377378126127
Completed391391387185172183375371126123
Not completed55102532704
Withdrew: Adverse events unrelated to study drug0121001500
Withdrew: Other reasons4141420000
Withdrew: Subject no longer meets study criteria1210100100
Withdrew: Subject withdrew consent0030010103
Withdrew: Subject request to discontinue study treatment0100000001
Withdrew: Death0000001000
Treatment Period
Participant flow — Treatment Period
MilestonePart 1-Arm B: Nivo + IpiPart 1-Arm A: NivolumabPart 1-Arm C: ChemotherapyPart 1-Arm D: Nivo + IpiPart 1-Arm G: Nivo + ChemoPart 1-Arm F: ChemotherapyPart 2 - Arm H: Nivolumab + ChemotherapyPart 2 - Arm I: ChemotherapyPart 3 -Arm J: Nivolumab + IpilimumabPart 3 - Arm K: Chemotherapy
Started391391387185172183375371126123
Completed4537941420324083037
Not completed34635429317115215133528812686
Withdrew: Not reported86442114852
Withdrew: Other reasons561275188211
Withdrew: Administrative reason by sponsor0300000000
Withdrew: Participant meet no longer study criteria1100110100
Withdrew: Poor/non compliance1020011001
Withdrew: Maximum clinical benefit3311303222
Withdrew: Lost to follow-up0011002200
Withdrew: Participant withdrew consent5533133323
Withdrew: Participant request to discontinue treatment53155361315418
Withdrew: Adverse event unrelated to study drug232922181115251942
Withdrew: Death4700126590
Withdrew: Study drug toxicity7951313912255230209
Withdrew: Disease progression21224020293113962081955946
Withdrew: Pregnancy0000000001
Withdrew: Other0000000001

Outcome measures

PrimaryProgression-Free Survival Per BICR

Progression-Free Survival then (PFS) is defined as the time between the date of randomization and the date of first documented disease progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first based on Kaplan-Meier estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From randomization untill disease progression or death, whichever occurs first (up to approximately 481 weeks)
Reported as:
Median · months
Progression-Free Survival Per BICR
monthsPart 1-Arm B: Nivo + IpiPart 1-Arm A: NivolumabPart 1-Arm C: ChemotherapyPart 1-Arm D: Nivo + IpiPart 1-Arm G: Nivo + ChemoPart 1-Arm F: ChemotherapyPart 2 - Arm H: Nivolumab + ChemotherapyPart 2 - Arm I: ChemotherapyPart 3 -Arm J: Nivolumab + IpilimumabPart 3 - Arm K: Chemotherapy
Progression-Free Survival Per BICR5.06 (4.07 to 6.31)4.17 (3.22 to 5.32)5.55 (4.63 to 5.82)4.90 (3.15 to 6.28)5.55 (4.63 to 6.90)4.70 (4.21 to 5.59)8.34 (7.10 to 9.59)5.52 (4.47 to 5.85)5.78 (4.14 to 8.34)5.49 (4.37 to 6.77)
Statistical analysis
  • Part 1-Arm B: Nivo + Ipi vs Part 1-Arm C: Chemotherapy · Hazard ratio (hr): 0.79 · 95% CI 0.67 to 0.93
  • Part 1-Arm A: Nivolumab vs Part 1-Arm C: Chemotherapy · Hazard ratio (hr): 0.95 · 95% CI 0.81 to 1.12
  • Part 1-Arm B: Nivo + Ipi vs Part 1-Arm A: Nivolumab · Hazard ratio (hr): 0.85 · 95% CI 0.72 to 0.99
  • Part 1-Arm D: Nivo + Ipi vs Part 1-Arm F: Chemotherapy · Cox proportional hazard: 0.76 · 95% CI 0.60 to 0.97
  • Part 1-Arm G: Nivo + Chemo vs Part 1-Arm F: Chemotherapy · Hazard ratio (hr): 0.74 · 95% CI 0.59 to 0.93
  • Part 2 - Arm H: Nivolumab + Chemotherapy vs Part 2 - Arm I: Chemotherapy · Hazard ratio (hr): 0.61 · 95% CI 0.52 to 0.72
  • Part 3 -Arm J: Nivolumab + Ipilimumab vs Part 3 - Arm K: Chemotherapy · Hazard ratio (hr): 0.66 · 95% CI 0.49 to 0.89
PrimaryOverall Survival

OS for all randomized participants is the time between randomization date and the date of death from any cause.

Time frame:
From randomization untill death or last follow up whichever occurs first (up to approximately 481 weeks)
Reported as:
Median · months
Overall Survival
monthsPart 1-Arm B: Nivo + IpiPart 1-Arm A: NivolumabPart 1-Arm C: ChemotherapyPart 1-Arm D: Nivo + IpiPart 1-Arm G: Nivo + ChemoPart 1-Arm F: ChemotherapyPart 2 - Arm H: Nivolumab + ChemotherapyPart 2 - Arm I: ChemotherapyPart 3 -Arm J: Nivolumab + IpilimumabPart 3 - Arm K: Chemotherapy
Overall Survival17.12 (14.95 to 20.17)15.70 (13.27 to 18.14)14.88 (12.71 to 16.72)17.45 (13.21 to 22.05)15.21 (12.29 to 19.78)12.19 (9.17 to 14.32)18.27 (15.84 to 21.65)14.72 (12.42 to 16.79)20.99 (16.95 to 25.17)15.11 (13.17 to 18.89)
Statistical analysis
  • Part 1-Arm B: Nivo + Ipi vs Part 1-Arm C: Chemotherapy · Hazard ratio (hr): 0.78 · 95% CI 0.67 to 0.91
  • Part 1-Arm A: Nivolumab vs Part 1-Arm C: Chemotherapy · Hazard ratio (hr): 0.91 · 95% CI 0.78 to 1.05
  • Part 1-Arm B: Nivo + Ipi vs Part 1-Arm A: Nivolumab · Hazard ratio (hr): 0.86 · 95% CI 0.74 to 1.01
  • Part 1-Arm D: Nivo + Ipi vs Part 1-Arm F: Chemotherapy · Hazard ratio (hr): 0.64 · 95% CI 0.51 to 0.79
  • Part 1-Arm G: Nivo + Chemo vs Part 1-Arm F: Chemotherapy · Hazard ratio (hr): 0.77 · 95% CI 0.63 to 0.96
  • Part 2 - Arm H: Nivolumab + Chemotherapy vs Part 2 - Arm I: Chemotherapy · Hazard ratio (hr): 0.75 · 95% CI 0.64 to 0.87
  • Part 3 -Arm J: Nivolumab + Ipilimumab vs Part 3 - Arm K: Chemotherapy · Hazard ratio (hr): 0.85 · 95% CI 0.64 to 1.14
SecondaryObjective Response Rate (ORR) Per BICR

Objective response rate (ORR) is defined as the number of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From randomization untill disease progression or death, whichever occurs first (up to approximately 481 weeks)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Per BICR
percentage of participantsPart 1-Arm B: Nivo + IpiPart 1-Arm A: NivolumabPart 1-Arm C: ChemotherapyPart 1-Arm D: Nivo + IpiPart 1-Arm G: Nivo + ChemoPart 1-Arm F: ChemotherapyPart 2 - Arm H: Nivolumab + ChemotherapyPart 2 - Arm I: ChemotherapyPart 3 -Arm J: Nivolumab + IpilimumabPart 3 - Arm K: Chemotherapy
Objective Response Rate (ORR) Per BICR36.4 (31.6 to 41.3)27.5 (23.2 to 32.2)29.7 (25.3 to 34.5)26.2 (20.1 to 33.1)37.9 (30.7 to 45.4)23.1 (17.3 to 29.8)52.3 (47.1 to 57.4)29.9 (25.3 to 34.8)38.1 (29.6 to 47.2)30.7 (22.8 to 39.5)
SecondaryPercentage of Participants With Symptom Deterioration at Week 12 Assessed Via Lung Cancer Symptom Scale

The Lung Cancer Symptom Scale (LCSS) is a disease measure of quality of life which evaluates six major lung cancer symptoms and their effect on overall distress and symptom severity, impact on day-to-day activities, and overall quality of life. This patient reported outcome (PRO) questionnaire assesses the following 6 symptoms items (appetite loss, fatigue, cough, dyspnea, hemoptysis, pain) and 3 summary global items (symptom distress, activity level, overall quality of life) for patients using visual analogue scales (VAS) (100 mm horizontal line) ranging from 0 (best rating) to 100 (worst rating). The LCSS average total score is sum of items 1 to 9 divided by the total number of items ((sum of items 1 to 9)/9) ranging from 0 to 100 where high score represent worst outcome. Disease-Related Symptom Deterioration by Week 12 defined as a 10 points or more increase from baseline in LCSS average score at any time (on or off-treatment) up to 95 days from randomization date.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Symptom Deterioration at Week 12 Assessed Via Lung Cancer Symptom Scale
percentage of participantsPart 1-Arm B: Nivo + IpiPart 1-Arm A: NivolumabPart 1-Arm C: ChemotherapyPart 1-Arm D: Nivo + IpiPart 1-Arm G: Nivo + ChemoPart 1-Arm F: ChemotherapyPart 2 - Arm H: Nivolumab + ChemotherapyPart 2 - Arm I: ChemotherapyPart 3 -Arm J: Nivolumab + IpilimumabPart 3 - Arm K: Chemotherapy
Percentage of Participants With Symptom Deterioration at Week 12 Assessed Via Lung Cancer Symptom Scale31.3 (26.8 to 36.1)35.4 (30.6 to 40.3)25.7 (21.5 to 30.3)33.2 (26.5 to 40.4)28.8 (22.3 to 36.1)37.6 (30.7 to 45.0)30.0 (25.4 to 34.9)24.3 (20.1 to 29.0)23.0 (16.0 to 31.4)26.0 (18.6 to 34.5)

Adverse events

Collected over Serious and non-serious adverse events were collected from first dose (Day 1) and 30 days after last dose of study therapy (up to approximately 105 months) and all cause mortality was collected from Day 1 and up to 481 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1-Arm B: Nivo + Ipi316/391 (80.8%)275/391 (70.3%)366/391 (93.6%)
Part 1-Arm A: Nivolumab333/391 (85.2%)239/391 (61.1%)356/391 (91%)
Part 1-Arm C: Chemotherapy339/387 (87.6%)213/387 (55%)361/387 (93.3%)
Part 1-Arm D: Nivo + Ipi159/185 (85.9%)128/185 (69.2%)172/185 (93%)
Part 1-Arm G: Nivo + Chemo157/172 (91.3%)112/172 (65.1%)167/172 (97.1%)
Part 1-Arm F: Chemotherapy174/183 (95.1%)91/183 (49.7%)165/183 (90.2%)
Part 2 - Arm H: Nivolumab + Chemotherapy314/375 (83.7%)240/375 (64%)357/375 (95.2%)
Part 2 - Arm I: Chemotherapy335/371 (90.3%)180/371 (48.5%)345/371 (93%)
Part 3 -Arm J: Nivolumab + Ipilimumab95/126 (75.4%)78/126 (61.9%)124/126 (98.4%)
Part 3 - Arm K: Chemotherapy94/123 (76.4%)60/123 (48.8%)121/123 (98.4%)
Most frequent serious events
Showing 10 of 560
Most frequent serious events
EventPart 1-Arm B: Nivo + IpiPart 1-Arm A: NivolumabPart 1-Arm C: ChemotherapyPart 1-Arm D: Nivo + IpiPart 1-Arm G: Nivo + ChemoPart 1-Arm F: ChemotherapyPart 2 - Arm H: Nivolumab + ChemotherapyPart 2 - Arm I: ChemotherapyPart 3 -Arm J: Nivolumab + IpilimumabPart 3 - Arm K: Chemotherapy
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)98/391102/39187/38739/18548/17241/18381/37578/37118/1269/123
PneumoniaInfections and infestations40/39129/39131/38718/18515/1728/18334/37529/37111/1268/123
PneumonitisRespiratory, thoracic and mediastinal disorders20/39111/3914/3877/1855/1721/18314/3751/37111/1260/123
Platelet count decreasedInvestigations0/3910/3913/3870/1850/1721/1836/3752/3713/1268/123
AnaemiaBlood and lymphatic system disorders4/3914/3919/3874/18510/1728/18314/37510/3711/1262/123
MyelosuppressionBlood and lymphatic system disorders0/3910/3910/3870/1850/1720/1831/3751/3710/1267/123
Immune-mediated hepatitisHepatobiliary disorders3/3910/3910/3870/1850/1720/1831/3750/3717/1260/123
DiarrhoeaGastrointestinal disorders6/3913/3914/3879/1851/1723/1836/3752/3714/1262/123
PyrexiaGeneral disorders5/3915/3915/3873/1853/1723/1836/3755/3716/1260/123
Febrile neutropeniaBlood and lymphatic system disorders0/3913/3919/3872/1854/1727/18316/3756/3710/1260/123
Most frequent other events
Showing 10 of 94
Most frequent other events
EventPart 1-Arm B: Nivo + IpiPart 1-Arm A: NivolumabPart 1-Arm C: ChemotherapyPart 1-Arm D: Nivo + IpiPart 1-Arm G: Nivo + ChemoPart 1-Arm F: ChemotherapyPart 2 - Arm H: Nivolumab + ChemotherapyPart 2 - Arm I: ChemotherapyPart 3 -Arm J: Nivolumab + IpilimumabPart 3 - Arm K: Chemotherapy
AnaemiaBlood and lymphatic system disorders47/39151/391159/38725/18580/17276/183174/375151/37163/12693/123
White blood cell count decreasedInvestigations8/3915/39119/3871/18517/1726/18341/37539/37122/12659/123
NauseaGastrointestinal disorders93/39181/391174/38741/18579/17274/183126/375133/37117/12630/123
Neutrophil count decreasedInvestigations9/39111/39150/3872/18531/17220/18352/37554/37116/12654/123
Platelet count decreasedInvestigations6/39110/39131/3872/18522/17225/18338/37530/37122/12649/123
HyponatraemiaMetabolism and nutrition disorders39/39117/39120/38714/18511/1728/18325/37516/37147/12618/123
ConstipationGastrointestinal disorders78/39170/391104/38736/18563/17253/18384/37583/37120/12625/123
Aspartate aminotransferase increasedInvestigations47/39137/39121/38727/18516/17212/18348/37525/37146/12632/123
Decreased appetiteMetabolism and nutrition disorders130/39197/391109/38761/18561/17252/183105/37588/37140/12634/123
Weight decreasedInvestigations37/39120/39122/38717/18514/1728/18332/37531/37144/12619/123

Baseline characteristics

Age, Customized
Age, Customized(Participants)Part 1-Arm B: Nivo + IpiPart 1-Arm A: NivolumabPart 1-Arm C: ChemotherapyPart 1-Arm D: Nivo + IpiPart 1-Arm G: Nivo + ChemoPart 1-Arm F: ChemotherapyPart 2 - Arm H: Nivolumab + ChemotherapyPart 2 - Arm I: ChemotherapyPart 3 -Arm J: Nivolumab + IpilimumabPart 3 - Arm K: ChemotherapyTotal
< 65199210207107919821419682841488
=>6519718619080868816318244431259
Sex: Female, Male
Sex: Female, Male(Participants)Part 1-Arm B: Nivo + IpiPart 1-Arm A: NivolumabPart 1-Arm C: ChemotherapyPart 1-Arm D: Nivo + IpiPart 1-Arm G: Nivo + ChemoPart 1-Arm F: ChemotherapyPart 2 - Arm H: Nivolumab + ChemotherapyPart 2 - Arm I: ChemotherapyPart 3 -Arm J: Nivolumab + IpilimumabPart 3 - Arm K: ChemotherapyTotal
Female1411241374947611131151820825
Male2552722601381301252642631081071922
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1-Arm B: Nivo + IpiPart 1-Arm A: NivolumabPart 1-Arm C: ChemotherapyPart 1-Arm D: Nivo + IpiPart 1-Arm G: Nivo + ChemoPart 1-Arm F: ChemotherapyPart 2 - Arm H: Nivolumab + ChemotherapyPart 2 - Arm I: ChemotherapyPart 3 -Arm J: Nivolumab + IpilimumabPart 3 - Arm K: ChemotherapyTotal
White299317305143136133272266001871
Black465022130023
Asian8467824138459394126127797
Other5631158120041
American Indian or Alaska Native402201310013
Native Hawaiian or other pacific islander00000001001
Not Reported00000001001
08

Study locations

290 sites
  • Southern Cancer Center, Inc.
    Mobile, Alabama 36608, United States
  • Local Institution - 0017
    San Francisco, California 94115, United States
  • Local Institution - 0021
    New Haven, Connecticut 06520, United States
  • Local Institution - 0001
    Atlanta, Georgia 30322, United States
  • Local Institution - 0013
    Marietta, Georgia 30060, United States
  • Local Institution - 0004
    Lexington, Kentucky 40503, United States
  • Local Institution - 0115
    St Louis, Missouri 63110, United States
  • Local Institution - 0005
    Buffalo, New York 14263, United States
  • Local Institution - 0019
    New York, New York 10065, United States
  • Local Institution - 0014
    Cleveland, Ohio 44106, United States
  • Local Institution - 0009
    Columbus, Ohio 43210, United States
  • Local Institution - 0007
    Allentown, Pennsylvania 18103, United States
  • Local Institution - 0075
    Langhorne, Pennsylvania 19047, United States
  • Local Institution - 0299
    Philadelphia, Pennsylvania 19107, United States
  • Local Institution - 0012
    Philadelphia, Pennsylvania 19111-2412, United States
  • Local Institution - 0015
    Sayre, Pennsylvania 18840, United States
  • Local Institution - 0008
    Charleston, South Carolina 29425, United States
  • Local Institution - 0080
    Greenville, South Carolina 29605, United States
  • Local Institution - 0010
    Greenville, South Carolina 29607, United States
  • Local Institution - 0020
    Nashville, Tennessee 37232, United States
  • Local Institution - 0306
    Dallas, Texas 75390-8852, United States
  • Local Institution - 0003
    Dallas, Texas 75390, United States
  • Local Institution - 0102
    Houston, Texas 77030, United States
  • Local Institution - 0011
    Salt Lake City, Utah 84108, United States
  • Local Institution - 0074
    Kennewick, Washington 99336, United States
  • Local Institution - 0170
    Berazategui, Buenos Aires 1880, Argentina
  • Local Institution - 0171
    Capital Federal, Buenos Aires 1426, Argentina
  • Local Institution - 0172
    Ciudad Autonoma de Buenos Aire, Buenos Aires 1181, Argentina
  • Local Institution - 0176
    Ciudad de Buenos Aires, Buenos Aires 1025, Argentina
  • Local Institution - 0296
    Mar del Plata, Buenos Aires 7600, Argentina
  • Local Institution - 0130
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Local Institution - 0268
    Córdoba, 5000, Argentina
  • Local Institution - 0272
    Córdoba, 5016, Argentina
  • Local Institution - 0297
    Córdoba, X50004FHP, Argentina
  • Local Institution - 0177
    Viedma, 8500, Argentina
  • Local Institution - 0182
    Garran, Australian Capital Territory 2605, Australia
  • Local Institution - 0301
    Blacktown, New South Wales 2148, Australia
  • Local Institution - 0300
    Gosford, New South Wales 2250, Australia
  • Local Institution - 0045
    Brisbane, Queensland 4102, Australia
  • Local Institution - 0046
    Elizabeth Vale, South Australia 5112, Australia
  • Local Institution - 0043
    Clayton, Victoria 3168, Australia
  • Local Institution - 0042
    Fitzroy, Victoria 3065, Australia
  • Local Institution - 0180
    Perth, Western Australia 6150, Australia
  • Local Institution - 0040
    Murdoch, 6150, Australia
  • Local Institution - 0183
    North Tamworth, 2340, Australia
  • Local Institution - 0241
    Graz, 8036, Austria
  • Local Institution - 0240
    Vienna, 1090, Austria
  • Local Institution - 0239
    Wels, 4600, Austria
  • Local Institution - 0034
    Charleroi, Hainaut 6060, Belgium
  • Local Institution - 0121
    Roeselare, West-Vlaanderen 8800, Belgium
  • Local Institution - 0030
    Edegem, 2650, Belgium
  • Local Institution - 0031
    Ghent, 9000, Belgium
  • Local Institution - 0117
    Hasselt, 3500, Belgium
  • Local Institution - 0033
    Sint-Niklaas, 9100, Belgium
  • Local Institution - 0125
    Salvador, Estado de Bahia 40170-110, Brazil
  • Local Institution - 0124
    Ijuí, Rio Grande do Sul 98700-000, Brazil
  • Local Institution - 0123
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Local Institution - 0127
    Barretos, São Paulo 14784-400, Brazil
  • Local Institution - 0129
    Rio de Janeiro, 20231-050, Brazil
  • Local Institution - 0144
    São Paulo, 01321-001, Brazil
  • Local Institution - 0126
    São Paulo, 01509-010, Brazil
  • Local Institution - 0128
    São Paulo, 05403-010, Brazil
  • Local Institution - 0103
    Edmonton, Alberta T6G 1Z2, Canada
  • Local Institution - 0290
    St. John's, Newfoundland and Labrador A1B 3V6, Canada
  • Local Institution - 0104
    London, Ontario N6A 5W9, Canada
  • Local Institution - 0122
    Montreal, Quebec H3T 1E2, Canada
  • Local Institution - 0106
    Québec, Quebec G1J 1Z4, Canada
  • Local Institution - 0302
    Québec, Quebec G1V 4G5, Canada
  • Local Institution - 0107
    Rimouski, Quebec G5L 5T1, Canada
  • Local Institution - 0291
    Sherbrooke, Quebec J1H 5N4, Canada
  • Local Institution - 0292
    Trois-Rivières, Quebec G8Z 3R9, Canada
  • Local Institution - 0173
    Santiago, Santiago Metropolitan 7500921, Chile
  • Local Institution - 0131
    Santiago, Santiago Metropolitan 8420383, Chile
  • Local Institution - 0174
    Viña del Mar, Valparaiso 254 0364, Chile
  • Local Institution - 0380
    Hefei, Anhui 230001, China
  • Local Institution - 0313
    Beijing, Beijing Municipality 100001, China
  • Local Institution - 0315
    Beijing, Beijing Municipality 100021, China
  • Local Institution - 0316
    Beijing, Beijing Municipality 100021, China
  • Local Institution - 0314
    Beijing, Beijing Municipality 100032, China
  • Local Institution - 0365
    Chongqing, Chongqing Municipality 400037, China
  • Local Institution - 0364
    Chongqing, Chongqing Municipality 400038, China
  • Local Institution - 0378
    Chongqing, Chongqing Municipality 400042, China
  • Local Institution - 0322
    Guangzhou, Guangdong 510060, China
  • Local Institution - 0372
    Guangzhou, Guangdong 510095, China
  • Local Institution - 0319
    Guanzhou, Guangdong 510080, China
  • Local Institution - 0323
    Haikou, Hainan 570311, China
  • Local Institution - 0325
    Haerbin, Heilongjiang 150081, China
  • Local Institution - 0324
    Zhengzhou, Henan 0, China
  • Local Institution - 0379
    Zhengzhou, Henan 450052, China
  • Local Institution - 0375
    Wuhan, Hubei 430024, China
  • Local Institution - 0362
    Changsha, Hunan 410013, China
  • Local Institution - 0347
    Nanchang, Jiangxi 0, China
  • Local Institution - 0329
    Changchun, Jilin 130012, China
  • Local Institution - 0361
    Changchun, Jilin 130021, China
  • Local Institution - 0359
    Shenyang, Liaoning 110000, China
  • Local Institution - 0371
    Xi'an, Shaanxi 710061, China
  • Local Institution - 0333
    Xi'an, Shan3xi 710038, China
  • Local Institution - 0360
    Qingdao, Shandong 266061, China
  • Local Institution - 0336
    Shanghai, Shanghai Municipality 200030, China
  • Local Institution - 0334
    Shanghai, Shanghai Municipality 200032, China

Showing the first 100 of 290 sites across 33 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Peters S, Paz-Ares LG, Reck M, Carbone DP, Brahmer JR, Borghaei H, Lu S, O'Byrne KJ, John T, Ciuleanu TE, Schenker M, Bernabe Caro R, Nishio M, Cobo M, Lee JS, Zurawski B, Pluzanski A, Aoyama T, Tschaika M, Devas V, Grootendorst DJ, Ramalingam SS. Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis. J Thorac Oncol. 2025 Jan;20(1):94-108. doi: 10.1016/j.jtho.2024.09.1439. Epub 2024 Oct 4. PubMed 39369790 ↗
  • Mason M, Lapuente-Santana O, Halkola AS, Wang W, Mall R, Xiao X, Kaufman J, Fu J, Pfeil J, Banerjee J, Chung V, Chang H, Chasalow SD, Lin HY, Chai R, Yu T, Finotello F, Mirtti T, Mayranpaa MI, Bao J, Verschuren EW, Ahmed EI, Ceccarelli M, Miller LD, Monaco G, Hendrickx WRL, Sherif S, Yang L, Tang M, Gu SS, Zhang W, Zhang Y, Zeng Z, Das Sahu A, Liu Y, Yang W, Bedognetti D, Tang J, Eduati F, Laajala TD, Geese WJ, Guinney J, Szustakowski JD, Vincent BG, Carbone DP. A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer. J Transl Med. 2024 Feb 21;22(1):190. doi: 10.1186/s12967-023-04705-3. PubMed 38383458 ↗
  • Brahmer JR, Lee JS, Ciuleanu TE, Bernabe Caro R, Nishio M, Urban L, Audigier-Valette C, Lupinacci L, Sangha R, Pluzanski A, Burgers J, Mahave M, Ahmed S, Schoenfeld AJ, Paz-Ares LG, Reck M, Borghaei H, O'Byrne KJ, Gupta RG, Bushong J, Li L, Blum SI, Eccles LJ, Ramalingam SS. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. J Clin Oncol. 2023 Feb 20;41(6):1200-1212. doi: 10.1200/JCO.22.01503. Epub 2022 Oct 12. PubMed 36223558 ↗
  • Reck M, Ciuleanu TE, Lee JS, Schenker M, Audigier-Valette C, Zurawski B, Linardou H, Otterson GA, Salman P, Nishio M, de la Mora Jimenez E, Lesniewski-Kmak K, Albert I, Ahmed S, Syrigos K, Penrod JR, Yuan Y, Blum SI, Nathan FE, Sun X, Moreno-Koehler A, Taylor F, O'Byrne KJ. First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1. J Thorac Oncol. 2021 Apr;16(4):665-676. doi: 10.1016/j.jtho.2020.12.019. Epub 2021 Jan 21. PubMed 33485960 ↗
  • Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28. PubMed 31562796 ↗
  • Reck M, Schenker M, Lee KH, Provencio M, Nishio M, Lesniewski-Kmak K, Sangha R, Ahmed S, Raimbourg J, Feeney K, Corre R, Franke FA, Richardet E, Penrod JR, Yuan Y, Nathan FE, Bhagavatheeswaran P, DeRosa M, Taylor F, Lawrance R, Brahmer J. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. Eur J Cancer. 2019 Jul;116:137-147. doi: 10.1016/j.ejca.2019.05.008. Epub 2019 Jun 11. PubMed 31195357 ↗
  • Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O'Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16. PubMed 29658845 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Oct 2024, 110 months.

Results were first posted in Oct 2025, 1 year after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 110 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2015
First posted
Jun 23, 2015
StartActual
Aug 5, 2015
Primary completionActual
Oct 25, 2024
CompletionActual
Oct 25, 2024
Results first posted
Oct 30, 2025
Last update
Oct 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02477826
Responsible party
Sponsor
First posted
Jun 23, 2015
Start date
Aug 5, 2015
Primary completion
Oct 25, 2024
Completion
Oct 25, 2024
Results posted
Oct 30, 2025
Last update
Oct 30, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab · Carboplatin · Cisplatin · Gemcitabine · Pemetrexed · Paclitaxel

Start the discussion